Group A was obese associated NAFLD with abnormal liver test ( n =60),group B was obese without NAFLD( n =16), group C was obese associated NAFLD( n =12),group D was obese with both ALT and AST elevation ( n =19).

• A组为肥胖伴NAFLD和肝损伤组 (60例 ) ,B组为无脂肪肝肥胖组 (16例 ) ,C组为肥胖伴NAFLD组 (12例 ) ,D组为丙氨酸转氨酶 (ALT)和天冬氨酸转氨酶 (AST)均升高组 (19例 ) ,其中A组给予奥利司他 12 0mg ,每日 3次 ,结合低热卡饮食 ,共治疗 2 4周。